Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on July 10, 2015. The filing reports the entry into a Material Definitive Agreement to acquire JT Pharmacy, Inc. D/B/A Central Allen Pharmacy ("CAP"), a compounding and retail pharmacy located in Allen, Texas.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The only financial data disclosed relates to the proposed acquisition:
- Acquisition Consideration: $360,000 in cash.
- Inventory Adjustment: Additional cash payment equal to verified inventory value, capped at $60,000.
- Total Potential Consideration: Up to $420,000.
Material Changes
The primary material change is the execution of a Stock Purchase Agreement to acquire CAP. The transaction is contingent upon the issuance of a license for sterile compounding at CAP's facility by the Texas state board of pharmacy. An inspection is scheduled for July 20, 2015.
Outlook, Risks, and Contingencies
Closing Conditions: The acquisition is expected to close on or before August 31, 2015, subject to the satisfaction of closing conditions, including the sterile compounding license and an employment arrangement with one of the sellers.
Termination Rights: The agreement may be terminated by mutual agreement or by either party if the acquisition has not closed by September 30, 2015.
Risks: Forward-looking statements highlight risks regarding transaction delays or failure to close, integration difficulties, and regulatory developments impacting compounding pharmacies.
Investor Verification Checklist
- Confirm the outcome of the Texas state board of pharmacy inspection scheduled for July 20, 2015.
- Verify the final closing date and whether the sterile compounding license was granted.
- Monitor for any termination of the agreement if the September 30, 2015 deadline is not met.
- Review subsequent filings for the actual inventory value paid at closing.